Progress in Hematology Basic and Clinical Updates in Multiple Myeloma

International Journal of Hematology

, Volume 97, Issue 3, pp 333-344

Current approaches for the treatment of multiple myeloma

  • Reiko WatanabeAffiliated withDivision of Hematology, Saitama Medical Center, Saitama Medical University Email author 
  • , Michihide TokuhiraAffiliated withDivision of Hematology, Saitama Medical Center, Saitama Medical University
  • , Masahiro KizakiAffiliated withDivision of Hematology, Saitama Medical Center, Saitama Medical University

Abstract

The development of novel therapeutic agents over the past decade, including the proteasome inhibitor, bortezomib, and the immunomodulatory drugs, lenalidomide and thalidomide, has resulted in improved outcomes for patients with multiple myeloma. However, there is still considerable controversy as to which regimen should be used as first-line therapy, which patients should be considered for autologous or allogeneic transplantation, and how consolidation or maintenance therapy is used in patients that have a good response to first-line therapy. The present paper will review clinical evidence from previous and ongoing studies to explore issues related to these questions.

Keywords

Multiple myeloma Bortezomib Lenalidomide Thalidomide Stem cell transplantation